{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:32:58Z","timestamp":1791340378602,"version":"4.3.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["AN372\/29-1"],"award-info":[{"award-number":["AN372\/29-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["30-1"],"award-info":[{"award-number":["30-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1053\/j.ajkd.2024.02.015","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:50:05Z","timestamp":1713189005000},"page":"495-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Erythrocytosis and CKD: A Review"],"prefix":"10.1053","volume":"84","author":[{"given":"Mabel","family":"Aoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.ajkd.2024.02.015_bib1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1751-553X.2008.01102.x","article-title":"The classification and diagnosis of erythrocytosis","volume":"30","author":"McMullin","year":"2008","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.02.015_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ajh.26920","article-title":"JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.02.015_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.critrevonc.2007.06.006","article-title":"Pathophysiology of anemia and erythrocytosis","volume":"64","author":"Hodges","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"20","key":"10.1053\/j.ajkd.2024.02.015_bib4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.ajkd.2024.02.015_bib5","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1097\/HJH.0000000000001805","article-title":"Gaisb\u00f6ck syndrome (polycythemia and hypertension) revisited: results from the national inpatient sample database","volume":"36","author":"Krishnamoorthy","year":"2018","journal-title":"J\u00a0Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2024.02.015_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5045\/br.2021.2021111","article-title":"Causes of erythrocytosis and its impact as a risk factor for thrombosis according to etiology: experience in a referral center in Mexico City","volume":"56","author":"Olivas-Martinez","year":"2021","journal-title":"Blood Res"},{"issue":"4","key":"10.1053\/j.ajkd.2024.02.015_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-021-00463-x","article-title":"Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera","volume":"11","author":"Nguyen","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/153537020322800101","article-title":"Erythropoietin: physiology and pharmacology update","volume":"228","author":"Fisher","year":"2003","journal-title":"Exp Biol Med (Maywood)"},{"issue":"Pt 6","key":"10.1053\/j.ajkd.2024.02.015_bib9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","article-title":"Regulation of erythropoietin production","volume":"589","author":"Jelkmann","year":"2011","journal-title":"J\u00a0Physiol"},{"key":"10.1053\/j.ajkd.2024.02.015_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-042921-102602","article-title":"Regulation of erythropoiesis by the hypoxia-inducible factor pathway: effects of genetic and pharmacological perturbations","volume":"74","author":"Semenza","year":"2023","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2141.2002.03386.x","article-title":"Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia","volume":"117","author":"Messinezy","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.02.015_bib12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.transproceed.2009.01.069","article-title":"Autosomal-dominant polycystic kidney disease and kidney transplantation: experience of a single center","volume":"41","author":"Gon\u00e7alves","year":"2009","journal-title":"Transplant Proc"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2024.02.015_bib13","first-page":"S30","article-title":"Spontaneous erythrocytosis in a patient on chronic hemodialysis","volume":"13","author":"Adeniyi","year":"2009","journal-title":"Hemodial Int"},{"issue":"3","key":"10.1053\/j.ajkd.2024.02.015_bib14","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11255-006-9014-8","article-title":"Secondary polycythaemia associated with unilateral renal cystic disease","volume":"39","author":"Blake-James","year":"2007","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.02.015_bib15","first-page":"1743","article-title":"Polycythemia secondary to renal cysts","volume":"35","author":"Fasolino","year":"2022","journal-title":"J\u00a0Nephrol"},{"key":"10.1053\/j.ajkd.2024.02.015_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.kint.2021.03.011","article-title":"From kidney injury to kidney cancer","volume":"100","author":"Peired","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2024.02.015_bib18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1523-1755.2003.00850.x","article-title":"Posttransplant erythrocytosis","volume":"63","author":"Vlahakos","year":"2003","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0272-6386(82)80041-3","article-title":"A\u00a0matched-pair control study of postrenal transplant polycythemia","volume":"2","author":"Frei","year":"1982","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2024.02.015_bib20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1399-0012.2008.00947.x","article-title":"Post-transplant erythrocytosis: a disappearing phenomenon?","volume":"23","author":"Kiberd","year":"2009","journal-title":"Clin Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2024.02.015_bib21","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.transproceed.2009.07.021","article-title":"Effect of angiotensin II type-1 receptor blockers on stable allograft kidneys: prospective randomized study","volume":"41","author":"Nouri-Majalan","year":"2009","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1053\/j.ajkd.2024.02.015_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/ejh.13696","article-title":"Post-transplantation erythrocytosis in kidney transplant recipients\u2014a retrospective cohort study","volume":"107","author":"Hofstetter","year":"2021","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1053\/j.ajkd.2024.02.015_bib23","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/tri.14016","article-title":"Risk factors and outcomes of post-transplant erythrocytosis among adult kidney transplant recipients: a systematic review and meta-analysis","volume":"34","author":"Mekraksakit","year":"2021","journal-title":"Transpl Int"},{"issue":"10","key":"10.1053\/j.ajkd.2024.02.015_bib24","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00277-023-05417-w","article-title":"Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension","volume":"102","author":"Mulas","year":"2023","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1053\/j.ajkd.2024.02.015_bib25","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/j.transproceed.2005.08.023","article-title":"Erythrocytosis after renal transplantation: review of 101 cases","volume":"37","author":"Einollahi","year":"2005","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1053\/j.ajkd.2024.02.015_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1542-4758.2010.00461.x","article-title":"Polycythemia due to obstructive sleep apnea in a patient on hemodialysis","volume":"14","author":"Nistico","year":"2010","journal-title":"Hemodial Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12890-019-0933-4","article-title":"China collaborative study on AKI (CCS-AKI). High hemoglobin is associated with increased in-hospital death in patients with chronic obstructive pulmonary disease and chronic kidney disease: a retrospective multicenter population-based study","volume":"19","author":"Xu","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1053\/j.ajkd.2024.02.015_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2022.1011964","article-title":"Where do you live and what do you do? Two questions that might impact your kidney health","volume":"2","author":"Aoun","year":"2022","journal-title":"Front Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2024.02.015_bib29","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1681\/ASN.2010121316","article-title":"High altitude renal syndrome (HARS)","volume":"22","author":"Arestegui","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.03.027","article-title":"Clinicopathological characteristics of high-altitude polycythemia-related kidney disease in Tibetan inhabitants","volume":"102","author":"Wang","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2024.02.015_bib31","first-page":"263","article-title":"Higher prevalence of unrecognized kidney disease at high altitude","volume":"31","author":"Hurtado-Arestegui","year":"2018","journal-title":"J\u00a0Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.02.015_bib32","doi-asserted-by":"crossref","first-page":"R504","DOI":"10.1152\/ajpregu.00102.2021","article-title":"Global REACH 2018: volume regulation in high-altitude Andeans with and without chronic mountain sickness","volume":"321","author":"Steele","year":"2021","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.02.015_bib33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1053\/ajkd.2002.33380","article-title":"Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia","volume":"39","author":"Jefferson","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"9307","key":"10.1053\/j.ajkd.2024.02.015_bib34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0140-6736(02)07812-1","article-title":"Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial","volume":"359","author":"Plata","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2024.02.015_bib35","first-page":"286","article-title":"Treatment of focal and segmental glomerulosclerosis secondary to high altitude polycythemia with acetazolamide","volume":"23","author":"Vizcarra-Vizcarra","year":"2022","journal-title":"High Alt Med Biol"},{"key":"10.1053\/j.ajkd.2024.02.015_bib36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/asheducation-2005.1.195","article-title":"A\u00a0unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases","author":"Vainchenker","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1053\/j.ajkd.2024.02.015_bib37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1053\/j.ajkd.2024.02.015_bib38","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3390\/cancers12071810","article-title":"Aetiology of myeloproliferative neoplasms","volume":"12","author":"McMullin","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1053\/j.ajkd.2024.02.015_bib39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ajkd.2024.02.015_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17474086.2022.2039117","article-title":"Renal disease associated with chronic myeloproliferative neoplasms","volume":"15","author":"Lucijanic","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.amjms.2021.10.009","article-title":"Clinical and pathological features of renal presentations in polycythemia vera","volume":"363","author":"Yang","year":"2022","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2024.02.015_bib43","first-page":"405","article-title":"Polycythemia vera: thinking beyond the hematocrit","volume":"14","author":"Waggoner","year":"2023","journal-title":"J\u00a0Adv Pract Oncol"},{"issue":"32","key":"10.1053\/j.ajkd.2024.02.015_bib44","doi-asserted-by":"crossref","first-page":"E913","DOI":"10.1503\/cmaj.191587","article-title":"Investigation and management of erythrocytosis","volume":"192","author":"Mithoowani","year":"2020","journal-title":"CMAJ"},{"key":"10.1053\/j.ajkd.2024.02.015_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103785","article-title":"Erythrocytosis associated with IgA nephropathy","volume":"75","author":"Cohen","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"14","key":"10.1053\/j.ajkd.2024.02.015_bib47","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033493","article-title":"Clinical characterization of polycythemia vera associated with IgA nephropathy in a single Chinese center: a case series","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1053\/j.ajkd.2024.02.015_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2024.02.015_bib49","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2024.02.015_bib50","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.02.015_bib51","doi-asserted-by":"crossref","first-page":"E621","DOI":"10.1152\/ajpendo.00277.2023","article-title":"Novel perspectives regarding the physiologic mechanisms by which gliflozins induce reticulocytosis and erythrocytosis","volume":"325","author":"Heyman","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"10.1053\/j.ajkd.2024.02.015_bib52","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J\u00a0Clin Med Res"},{"issue":"9733","key":"10.1053\/j.ajkd.2024.02.015_bib53","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of\u00a0dapagliflozin in patients with type 2 diabetes who have\u00a0inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.ajkd.2024.02.015_bib54","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1053\/j.ajkd.2024.02.015_bib55","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","article-title":"Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"Dekkers","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1053\/j.ajkd.2024.02.015_bib56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","article-title":"Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial","volume":"66","author":"Gullaksen","year":"2023","journal-title":"Diabetologia"},{"issue":"6","key":"10.1053\/j.ajkd.2024.02.015_bib57","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","article-title":"SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes","volume":"79","author":"Zhuo","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2024.02.015_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae032","article-title":"How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial","author":"Wanner","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2024.02.015_bib59","doi-asserted-by":"crossref","first-page":"E276","DOI":"10.1002\/ajh.27034","article-title":"Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: a Mayo Clinic series of nine consecutive cases","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.ajkd.2024.02.015_bib60","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gfad171","article-title":"Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology","volume":"38","author":"Gangat","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2024.02.015_bib61","doi-asserted-by":"crossref","first-page":"E988","DOI":"10.9778\/cmajo.20210322","article-title":"Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review","volume":"10","author":"Chin-Yee","year":"2022","journal-title":"CMAJ Open"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib62","first-page":"92","article-title":"Hemochromatosis, erythrocytosis and the JAK2 p.V617F mutation","volume":"28","author":"Langabeer","year":"2017","journal-title":"EJIFCC"},{"key":"10.1053\/j.ajkd.2024.02.015_bib63","article-title":"Hemochromatosis gene mutation in persons developing erythrocytosis on combined testosterone and SGLT-2 inhibitor therapy","volume":"10","author":"Schumacher","year":"2022","journal-title":"J\u00a0Investig Med High Impact Case Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2024.02.015_bib64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jc.2018-01702","article-title":"Risk of erythrocytosis during concomitant testosterone and SGLT2-inhibitor treatment: a warning from two clinical cases","volume":"104","author":"Motta","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1053\/j.ajkd.2024.02.015_bib65","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/ndt\/gfad112","article-title":"SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA","volume":"38","author":"Mark","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"22","key":"10.1053\/j.ajkd.2024.02.015_bib66","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2024.02.015_bib67","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1053\/j.ajkd.2024.02.015_bib68","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS program collaborative group. canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2024.02.015_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107729","article-title":"Correction of anemia by dapagliflozin in patients with type 2 diabetes","volume":"34","author":"Stef\u00e1nsson","year":"2020","journal-title":"J\u00a0Diabetes Complications"},{"issue":"2","key":"10.1053\/j.ajkd.2024.02.015_bib70","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jcmm.17115","article-title":"Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis","volume":"26","author":"Tian","year":"2022","journal-title":"J\u00a0Cell Mol Med"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14632","article-title":"Successful withdrawal of erythropoiesis-stimulating agent after administration of an SGLT2 inhibitor, tofogliflozin, in people with diabetes","volume":"39","author":"Sato","year":"2022","journal-title":"Diabet Med"},{"issue":"8","key":"10.1053\/j.ajkd.2024.02.015_bib72","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2024.02.015_bib73","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1053\/j.ajkd.2024.02.015_bib74","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12933-023-02027-8","article-title":"Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial","volume":"22","author":"Koshino","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"26","key":"10.1053\/j.ajkd.2024.02.015_bib75","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood.2021013996","article-title":"JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy","volume":"138","author":"Gangat","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.ajkd.2024.02.015_bib76","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/dme.13706","article-title":"Unmasking and aggravation of polycythemia vera by canagliflozin","volume":"35","author":"Das","year":"2018","journal-title":"Diabet Med"},{"issue":"7","key":"10.1053\/j.ajkd.2024.02.015_bib77","doi-asserted-by":"crossref","first-page":"E165","DOI":"10.1002\/ajh.26933","article-title":"Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624007157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624007157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T19:00:32Z","timestamp":1726772432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624007157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0272638624007157"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.02.015","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythrocytosis and CKD: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}